BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes

During the development of colorectal cancer, tumor cells will generate some cancer stem cells with selfrenewal ability because they adapt to the environment. Therefore, in the treatment of colorectal cancer, it has certain potential clinical application value to effectively inhibit cancer stem cells. A small molecule EHMT-2 inhibitor, BIX-01294, was evaluated for its activity in inhibiting cancer stem cells in human colorectal cancer by in vitro and in vivo experiments. Transcriptome analysis was performed on BIX01294 treated cells for holistic analysis to elucidate how BIX-01294 inhibits the expression of genes related to cancer stem cells. The results show that BIX-01294 significantly inhibited the proliferative phenotype of human colorectal cancer in vivo and in vitro, reduced the proportion of cancer stem cells, and inhibited some stemness-related gene. Morever, it is synergistic with 5-fluorouracil in inhibiting the proliferation of colorectal cancer. In summary, EHMT-2 is a novel target of anti-tumor drugs. The combination of BIX-01294 and 5-fluorouracil has a synergistic therapeutic effect on human colorectal cancer. (c) 2021 Elsevier Inc. All rights reserved.

Automated summary

Colorectal cancer stem cells present challenges in treatment, but the EHMT-2 inhibitor BIX-01294 effectively inhibits their proliferation, with a synergistic therapeutic effect when combined with 5-fluorouracil.